H. Lundbeck A/S faces significant patent cliffs and a risky pipeline, but management's expense restructuring and Longboard acquisition can drive future growth. The $2.5B acquisition of Longboard ...

Only days after revealing an unsolicited buyout bid from Lundbeck, Avadel—which has already signed an agreement to sell itself to Alkermes—has officially determined that the Lundbeck offer is sweeter.

Lundbeck's new CEO has laid out a plan to maximize the value of the company's current portfolio, reorganize R&D, and deploy capital towards growth-sustaining M&A. The company aims to maximize the ...

Lundbeck announced this week that it will acquire Longboard Pharmaceuticals in a $2.6 billion deal, picking up the epilepsy drug bexicaserin in the process. The move — the largest to date for the ...

Seeking a new approval to curb agitation in Alzheimer's patients, Lundbeck and Otsuka Pharmaceutical are gearing up for an important test Friday. And it appears the FDA is open to a potential nod for ...

The board of directors of both companies have unanimously approved the transaction. The transaction is expected to close in the fourth quarter of 2024, subject to the tender of at least a majority of ...

Lundbeck HLUN B reported second-quarter results highlighted by revenue of DKK 4.9 billion, representing a 10% increase from the prior-year period. Continued strong performance from Lundbeck’s ...

Shares of Longboard Pharmaceuticals Inc. are surging more than 51% Monday, boosted by H. Lundbeck’s $2.6 billion deal to acquire the California-based clinical-stage biopharmaceutical company.

Longboard Pharmaceuticals LBPH announced that it is set to be acquired by Lundbeck A/S for $60 per share in cash, which brings the total deal value to $2.6 billion equity value and $2.5 billion ...

SAN FRANCISCO--(BUSINESS WIRE)--Otsuka America Pharmaceutical, Inc., (Otsuka) and Lundbeck US (Lundbeck) today presented positive efficacy and safety data from multiple Phase 3 studies of ...

COPENHAGEN, Jan 27 (Reuters) - Danish pharmaceutical group Lundbeck sold its stakes in a rival drugmaker and in four private equity funds, raising cash that analysts saw as earmarked for boosting its ...

Phase 3 clobazam trial gets good results treating seizures Company repeats will file application with FDA by year-end COPENHAGEN, Dec 6 (Reuters) - Danish drugmaker Lundbeck has got positive results ...